The phase III ICE study: Adjudiscloseant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer Gunter von Minckwitz, Toralf Reimer, Jochem Potenberg, Bettina Conrad, Heiko Graf, Holger Eidtmann, Marianne Just, Stephan Paepke, Elmar Stickeler, Georg Heinrich, Michael Untch, Volker Möbus, Christoph Thomssen, Christian Jackisch, Jens Huober, Sibylle Loibl, Valentina Nekljudova, Ulrike Nitz for the GBG / AGO-B / NOGGO / WSG study groups within the BIG framework Gunter von Minckwitz
17
Embed
The phase III ICE study: Adjudiscloseant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer Gunter.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
The phase III ICE study: Adjudiscloseant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancerGunter von Minckwitz, Toralf Reimer, Jochem Potenberg, Bettina Conrad, Heiko Graf, Holger Eidtmann, Marianne Just, Stephan Paepke, Elmar Stickeler, Georg Heinrich, Michael Untch, Volker Möbus, Christoph Thomssen, Christian Jackisch, Jens Huober, Sibylle Loibl, Valentina Nekljudova, Ulrike Nitz for the GBG / AGO-B / NOGGO / WSG study groups within the BIG framework
Gunter von Minckwitz
Dra. María del Rosario VidalJefa del Servicio de Oncología Clínica del Hospital de Morón
Estudio ICE Fase III: Ibandronato Adyuvante con o sin Capecitabina en Pacientes ancianas con cáncer de mama temprano con riesgo moderado o alto (GBG32, BIG 4-04)Gunter von Minckwitz, Toralf Reimer, Jochem Potenberg, Bettina Conrad, Heiko Graf, Holger Eidtmann, Marianne Just, Stephan Paepke, Elmar Stickeler, Georg Heinrich, Michael Untch, Volker Möbus, Christoph Thomssen, Christian Jackisch, Jens Huober, Sibylle Loibl, Valentina Nekljudova, Ulrike Nitz for the GBG / AGO-B / NOGGO / WSG study groups within the BIG framework